<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Cerebrovascular disease (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) and ischemic brain injury secondary to <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> are common causes of <z:hpo ids='HP_0000726'>dementia</z:hpo> and <z:hpo ids='HP_0001268'>cognitive decline</z:hpo> in the elderly </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> also contributes to cognitive loss in <z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> (AD) </plain></SENT>
<SENT sid="2" pm="."><plain>SUMMARY: Progress in understanding vascular <z:hpo ids='HP_0100543'>cognitive impairment</z:hpo> (VCI) and vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> (VaD) has resulted in promising symptomatic and preventive treatments </plain></SENT>
<SENT sid="3" pm="."><plain>Cholinergic deficits in VaD due to <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> of basal forebrain nuclei and cholinergic pathways can be treated with <z:chebi fb="0" ids="37733">cholinesterase inhibitors</z:chebi> used in AD </plain></SENT>
<SENT sid="4" pm="."><plain>Controlled clinical trials with <z:chebi fb="0" ids="53289,53290,53292">donepezil</z:chebi> and galantamine in patients with VaD, as well as in patients with AD plus <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>, have demonstrated improvement in cognition, behavior, and activities of daily living </plain></SENT>
<SENT sid="5" pm="."><plain>The <z:chebi fb="0" ids="31882">N-methyl-D-aspartate</z:chebi> receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> memantine stabilized progression of VaD compared with placebo </plain></SENT>
<SENT sid="6" pm="."><plain>Primary and secondary <z:hpo ids='HP_0001297'>stroke</z:hpo> prevention, in particular with control of <z:hpo ids='HP_0000822'>hypertension</z:hpo> and <z:hpo ids='HP_0003077'>hyperlipidemia</z:hpo>, can decrease VaD incidence </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: From a public health viewpoint, recognition of VCI before the development of <z:hpo ids='HP_0000726'>dementia</z:hpo> and correction of vascular burden on the brain may lead to a global decrease of incident <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
</text></document>